|1.||Humar, Atul: 9 articles (01/2015 - 04/2004)|
|2.||Humar, A: 5 articles (05/2010 - 09/2005)|
|3.||Lautenschlager, Irmeli: 4 articles (10/2015 - 01/2007)|
|4.||Rawlinson, William D: 4 articles (11/2014 - 03/2009)|
|5.||Rahbar, Afsar: 4 articles (07/2014 - 10/2011)|
|6.||Stragliotto, Giuseppe: 4 articles (07/2014 - 09/2013)|
|7.||Söderberg-Nauclér, Cecilia: 4 articles (11/2013 - 10/2011)|
|8.||Pescovitz, M D: 4 articles (06/2010 - 09/2007)|
|9.||Pascual, Manuel: 4 articles (01/2010 - 07/2005)|
|10.||Rabasseda, X: 4 articles (09/2006 - 05/2004)|
06/01/2010 - "valganciclovir, may provide effective exposure and therapeutic response in the treatment of CMV infection in SOT patients with adequate drug exposure and with the additional potential benefit of shortening the length of hospital stay, which may result in cost reduction and improved patient comfort."
07/01/2009 - ": She was started on valganciclovir, resulting in remission of her symptoms, improvement in inflammatory markers and clearing of detectable HHV8 viraemia : Valganciclovir is effective in treating symptomatic HHV8 infections without MCD."
04/01/2013 - "This article examines the safety and efficacy of valganciclovir in pediatric SOT patients, with a particular focus on prophylaxis of CMV infections. "
03/01/2015 - "In this study, we evaluated valganciclovir against disseminated adenovirus type 5 (Ad5) infection in our permissive immunosuppressed Syrian hamster model. "
12/01/2014 - " addition, in a double-blind randomized placebo-controlled trial in neonates with symptomatic congenital CMV infection, a 6-month course of valganciclovir was superior to the standard 6-week course of the same drug. "
11/01/2004 - "Six months after discontinuation of immunosuppressive therapy, CMV retinitis of the left eye occurred but was treated successfully with a second course of oral valganciclovir. "
01/01/2011 - "Valganciclovir is an essential drug for developing successful programs for management of CMV retinitis in China and throughout SE Asia."
01/01/2011 - "CMV retinitis has been clinically ignored, in part, because of the perceived complexity and expense of treatment, and this obstacle can be removed by making valganciclovir affordable and widely available. "
01/01/2011 - "The obvious way to improve clinical management of CMV retinitis is to screen all patients with CD4 counts < 100 cells/μL with indirect ophthalmoscopy at the time they first present for care, and to provide systemic treatment with oral valganciclovir when active CMV retinitis is detected. "
01/01/2010 - "In March 2001, the US Food and Drug Administration approved valganciclovir for the induction and maintenance treatment of CMV disease, including CMV retinitis. "
|3.||Acquired Immunodeficiency Syndrome (AIDS)
04/01/2010 - "We describe the first case of an AIDS patient with CMV pseudotumor responding to oral treatment with valganciclovir with complete resolution of the CMV mass. "
07/05/2002 - "Cytomegalovirus-induced hemorrhagic cystitis in AIDS patient treated successfully with valganciclovir."
04/01/2006 - "Treatment of cytomegalovirus retinitis with oral valganciclovir in an acquired immunodeficiency syndrome patient unresponsive to combination antiretroviral therapy."
08/01/2002 - "AIDS patients (median CD4 lymphocyte count of 140 cells/microL) with treated CMV retinitis (N = 212) received 900-mg once-daily valganciclovir maintenance therapy with courses of 900-mg twice-daily valganciclovir induction therapy as needed to treat progression. "
12/15/2001 - "Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis."
|4.||Cytomegalovirus Infections (Inclusion Disease)
08/01/2011 - "Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection."
02/01/2013 - "Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection."
01/01/2012 - "[Successful treatment of congenital cytomegalovirus infection with valganciclovir]."
08/01/2011 - "We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. "
04/15/2011 - "Five human immunodeficiency virus-seronegative participants received valganciclovir for up to six 4-week cycles at doses used for cytomegalovirus infection. "
01/01/2002 - "Valganciclovir: a new treatment for cytomegalovirus retinitis."
08/01/2002 - "A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis."
04/11/2002 - "A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis."
01/01/2010 - "Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients."
04/01/2006 - "Diagnosis of cytomegalovirus retinitis was made, and the patient began induction therapy with oral valganciclovir 900 mg twice a day for 3 weeks. "
|5.||DNA (Deoxyribonucleic Acid)
|6.||Immunoglobulin G (IgG)
|9.||Antiviral Agents (Antivirals)
|1.||Transplantation (Transplant Recipients)
|3.||Highly Active Antiretroviral Therapy (HAART)
|4.||Hematopoietic Stem Cell Transplantation